<DOC>
	<DOCNO>NCT01238861</DOCNO>
	<brief_summary>The primary objective study evaluate effect multiple-dose subcutaneous administration MEDI-563 adult uncontrolled asthma .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety MEDI-563 Adults With Uncontrolled Asthma</brief_title>
	<detailed_description>This Phase 2b , randomize , double-blind , placebo-controlled , dose-ranging study evaluate efficacy safety multiple-dose ( 7 dos ) subcutaneous administration benralizumab ( MEDI-563 ) adult subject uncontrolled asthma .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Age 18 75 year time screen Adequate contraception screen end trial Weight ( &gt; ) 45 kilogram ( kg ) less equal ( &lt; = ) 150 kg ( &gt; 100 pound [ lb ] &lt; =330 lb ) History physiciandiagnosed asthma least 12 month prior screen Physician prescribe daily use mediumdose highdose inhaled corticosteroid ( ) ( ICS ) plus longacting beta 2 agonist ( LABA ) least 12 month prior screen Willingness switch ICS/LABA combination product Dose asthma controller medication must stable least 30 day prior screen At least 2 documented asthma exacerbation 12 month prior screen require use systemic corticosteroid burst For subject 65 year age old , chest xray ( CXR ) chest compute tomography ( CT ) normal asthmatic population Ability willingness complete study Week 66 , need Week 92 . Known history allergy reaction component investigational product formulation History anaphylaxis biologic therapy Unexplained diarrhea within 30 day prior screen diagnosis helminth parasitic infestation within 6 month prior screen Use immunosuppressive medication within 3 month prior screen . Chronic oral prednisone equivalent 10 milligram ( mg ) daily 20 mg every day asthma allow Oral corticosteroid burst shortacting systemic corticosteroid within 30 day prior screen screening/runin period Acute upper low respiratory infection require antibiotic antiviral medication within 30 day prior screen screening/runin period Receipt immunoglobulin blood product within 30 day prior screen Receipt market investigational biologic within 4 month 5 halflives prior screen , whichever long Receipt investigational nonbiologic within 30 day 5 halflives prior screen , whichever longer Previously receive MEDI563 Any clinically relevant abnormal finding physical examination Past history clinically significant cardiac disease electrocardiogram ( ECG ) abnormality Breastfeeding lactate woman History alcohol drug abuse within 12 month prior screen History know primary immunodeficiency disorder Positive medical history hepatitis B C. Subjects history hepatitis B vaccination without history hepatitis B allow enrol A positive human immunodeficiency virus ( HIV ) test subject take antiretroviral medication History cigarette smoke equal ( &gt; = ) 10 packyears smoke within 12 month prior screen . Known exposure inhale occupational agent fumes establish diagnosis occupational asthma History cancer , except basal cell carcinoma situ carcinoma cervix treat apparent success curative therapy &gt; =12 month prior screen malignancy treat apparent success curative therapy &gt; =5 year prior screen Stable dose allergy vaccination regimen less 30 day prior screen Subjects unable demonstrate acceptable inhaler peak flow meter technique .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Benralizumab</keyword>
	<keyword>MEDI-563</keyword>
</DOC>